Academic medical center
Appears in 1 story · Last updated Sep 27, 2026
As of September 2026: Conducted the Phase 1a trial
A single infusion of a CRISPR gene-editing therapy kept LDL cholesterol about 52% lower and triglycerides about 48% lower for a full year in a 15-patient trial. It is the longest durability data yet for in vivo CRISPR in heart disease.
Updated Sep 27
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
